CR
Cardiol Therapeutics Inc.
CRDL · NASDAQ
$1.71 -2.28% (-$0.04)
1M -11.86%
Market Cap $282.1M
P/E Ratio -
Div. Yield -
ROE 193.63%
Bulios Fair Price
$1.37
19.9% downside
Current Price
$1.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRDL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 11.74x
P/FFO N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 22.57%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 193.63%
ROA 124.84%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 5.55x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
67 /100
Stable EPS volatility 20.06%
Profitable years 0
Beta 0.52x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRDL
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
David G. Elsley
Employees
18
Headquarters
Oakville
Upcoming events
12 NOV
Earnings
Upcoming earnings report